전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved402 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA anti-CD19 CAR T cells (RNA anti-CD19 CAR T cells)

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Discontinued
CGTLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Leukemia, Myeloid, Acute · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTLimited DatastaleThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleGenetix Biotherapeutics Inc.Phase 2

Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a (Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a)

Sickle Cell Disease · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleFondazione Matilde Tettamanti M…Phase 2

CARCIK-CD19 (CARCIK-CD19)

Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA CART19 cells (CD19 RNA redirected autologous T-cells, CD19 RNA redirected autologous T-cells (RNA CART19 cells))

Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Discontinued
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleInnovative Cellular Therapeutic…Preclinical

CD19CART (CD19CART)

Leukemia, B-Cell; Lymphoma, B-Cell · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 3Status Active
CGTLimited DatastaleBeijing BiotechPhase 1

CD20/BCMA-directed CAR-T cells (CD20/BCMA-directed CAR-T cells)

Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM) · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22CART infusion (CD22CART infusion)

Leukemia; Acute Lymphoblastic Leukemia · CD22

#CD22#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 2

Humanized CD7 CAR-T cells (Humanized CD7 CAR-T cells)

Refractory and Relapsed T Cell Lymphoma · T Lymphoblastic Leukemia/Lymphoma

#TLymphoblasticLeukemiaLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus Chidamide (Induction therapy-3 cycles of BvC, Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
CGTLimited DatastaleUniversity of Colorado, DenverPhase 1

UCD19 CAR T Cells (UCD19 CAR T Cells)

Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD123 CAR NK cells (Anti-CD123 CAR NK cells)

AML (Acute Myeloid Leukemia); BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) · AML (Acute Myeloid Leukemia)

#AMLAcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Preclinical

Anti-CD19 IL-10/IL15 CAR-NK (Anti-CD19 IL-10/IL15 CAR-NK)

Systemic Sclerosis (SSc); ANCA Associated Vasculitis (AAV) · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-CD19 UCAR-NK cells (Anti-CD19 UCAR-NK cells)

B-cell Lymphoma; B-cell Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Discontinued

6 / 21 pages

← PreviousNext →